A Chinese firm racing to develop a coronavirus vaccine has received additional funding from investors. Beijing-based Sinovac Biotech Ltd. obtained $15m from Advantech Capital and Vivo Capital, raising $7.5m from each of the investors. The new funds will be used to accelerate Sinovac’s candidate, CoronaVac, into Phase II development.
In April, the company announced a Phase I study of the inactivated virus product and is planning to start the...






